Largest Biotech Funding Rounds of June 2025: Overview of Notable Financings in the Bio-industry During This Month
In June 2025, the biotech sector witnessed a flurry of significant fundraising activities, with both private and public sectors setting new records.
The private biotech sector saw a total of nine rounds, raising $1.191 billion, marking North America's best performance in a long time. Notably, the largest private biotech funding round of the year, and indeed the largest overall, was secured by Cogent Biosciences in June. The company raised a non-dilutive investment of $400 million, facilitated by SLR Capital Partners, with $50 million drawn at closing, and an additional $100 million available during 2025. An additional $50 million for Cogent Biosciences will be available upon achievement of early commercial success, and the remaining $200 million is contingent on mutual agreement.
In the private biotech fundraising by funding type, Series A rounds had the most rounds, with six in total. Other notable large private rounds include Grin Therapeutics Series D at $140 million, Vima Therapeutics raising $60 million Series A, and AusperBio adding $50 million in a Series B+ round.
The public biotech sector also experienced a surge in fundraising, totaling $2.7 billion, making June the best month of the year so far. The largest public biotech financing was secured by Insmed, with a $750 million offering. Insmed intends to use the net proceeds from the offering for continued research and development of its candidate brensocatib, as well as pre-commercial and commercialization activities related to brensocatib.
In the public biotech funding by therapeutic subsector, oncology companies completed the most rounds. However, pulmonology secured the most amount raised, thanks to Insmed's $750 million round. Notable public offerings include Cidara Therapeutics raising $402.5 million and Merus bringing in $300 million.
Europe had two fewer rounds than North America but raised significantly less, with $504.42 million. Neurological conditions companies achieved the most rounds in the private biotech sector, raising a total of $430 million.
The first half of 2025 saw a general trend of very large private rounds early in the year, with a surge in large public offerings in June. This overview reflects the largest known individual biotech funding rounds monthly from January through June, providing a comprehensive view of the dynamic biotech funding landscape in 2025.
[1] Source: Various financial news outlets [2] Source: TechCrunch (for March AI/biotech crossover funding rounds) [3] Source: BusinessWire (for May and June private fundraising rounds) [4] Source: S&P Global Market Intelligence (for public IPO activity in February to April 2025)
- The largest private biotech funding round of the year, and indeed the largest overall, was secured by Cogent Biosciences, procuring a non-dilutive investment of $400 million.
- In June, the public biotech sector also experienced a surge in fundraising, with Insmed securing the largest public biotech financing of $750 million.
